淋巴管生成是急性GVHD的特征,抑制VEGFR-3可预防实验性GVHD
研究在小鼠同种异体造血干细胞移植模型及患者肠道活检中发现,急性移植物抗宿主病(aGVHD)与淋巴管生成相关;用抗血管内皮生长因子受体3(VEGFR-3)单克隆抗体抑制aGVHD相关淋巴管生成,可改善小鼠aGVHD并提高生存率,且不干扰造血植入、改善免疫重建,对移植后恶性淋巴瘤生长无显著影响。
要点
- aGVHD与肠道病变及淋巴结中的淋巴管生成相关。
- 抗VEGFR-3抗体抑制淋巴管生成,改善小鼠aGVHD并提高生存率。
- 抗VEGFR-3治疗不干扰造血植入,改善aGVHD受者免疫重建。
核心结论
- aGVHD与肠道病变和淋巴结中的淋巴管生成相关。
- 抗VEGFR-3治疗改善致死性aGVHD,淋巴管系统是同种异体造血干细胞移植中的新治疗靶点。
研究设计与样本
- 研究采用小鼠同种异体造血干细胞移植模型及患者肠道活检。
主要发现
- 在小鼠同种异体造血干细胞移植模型及患者肠道活检中,aGVHD与淋巴管生成相关。
- 用抗VEGFR-3单克隆抗体抑制aGVHD相关淋巴管生成,可改善小鼠aGVHD并提高生存率。
- 给予抗VEGFR-3抗体不干扰造血植入,并改善伴aGVHD的同种异体造血干细胞移植受者的免疫重建。
- 抗VEGFR-3治疗对移植后恶性淋巴瘤生长无显著影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymph vessels play a crucial role in immune reactions in health and disease. In oncology the inhibition of lymphangiogenesis is an established therapeutic concept for reducing metastatic spreading of tumor cells. During allogeneic tissue transplantation, the inhibition of lymphangiogenesis has been successfully used to attenuate graft rejection. Despite its critical importance for tumor growth, alloimmune responses, and inflammation, the role of lymphangiogenesis has not been investigated during allogeneic hematopoietic stem cell transplantation (allo-HSCT). We found that acute graft-versus-host disease (aGVHD) is associated with lymphangiogenesis in murine allo-HSCT models as well as in patient intestinal biopsies. Inhibition of aGVHD-associated lymphangiogenesis by monoclonal antibodies against vascular endothelial growth factor receptor 3 (VEGFR-3) ameliorated aGVHD and improved survival in murine models. The administration of anti-VEGFR-3 antibodies did not interfere with hematopoietic engraftment and improved immune reconstitution in allo-HSCT recipients with aGVHD. Anti-VEGFR-3 therapy had no significant impact on growth of malignant lymphoma after allo-HSCT. We conclude that aGVHD is associated with lymphangiogenesis in intestinal lesions and in lymph nodes. Our data show that anti-VEGFR-3 treatment ameliorates lethal aGVHD and identifies the lymphatic vasculature as a novel therapeutic target in the setting of allo-HSCT.
引用
- Mertlitz S, Shi Y, Kalupa M, et al. Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHD. Blood. 2017. PMID: 28096093. doi:10.1182/blood-2016-08-734210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。